Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

NCT07162181 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07162181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07162181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 7, 2025
Completion date
May 31, 2030
Enrollment
13 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, leukemia, lymphocytic, chronic, b-cell, lymphoma, non-hodgkin